These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20690806)

  • 41. Trastuzumab and vinorelbine in early stages of HER2-positive breast cancer.
    Ferrario C; Wong A; Gao T; Bouganim N; Aloyz R; Panasci LC
    J Chemother; 2011 Feb; 23(1):32-5. PubMed ID: 21482492
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer.
    Heinemann V; Di Gioia D; Vehling-Kaiser U; Harich HD; Heinrich B; Welt A; Ziske C; Deutsch G; Pihusch R; Kölbl H; Hegewisch-Becker S; Michl M; Stemmler HJ
    Ann Oncol; 2011 Mar; 22(3):603-608. PubMed ID: 20724574
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Efficacy and toxicity of trastuzumab combined vinorelbine in 21 patients with HER2 overexpressing metastatic breast cancer].
    Zhou NN; Liu DG; Teng XY; Jiang WQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1707-9. PubMed ID: 18819904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer.
    Morabito A; Longo R; Gattuso D; Carillio G; Massaccesi C; Mariani L; Bonginelli P; Amici S; De Sio L; Fanelli M; Torino F; Bonsignori M; Gasparini G
    Oncol Rep; 2006 Aug; 16(2):393-8. PubMed ID: 16820921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy).
    Schilling G; Bruweleit M; Harbeck N; Thomssen C; Becker K; Hoffmann R; Villena C; Schütte M; Hossfeld DK; Bokemeyer C; de Wit M
    Invest New Drugs; 2009 Apr; 27(2):166-72. PubMed ID: 18696011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.
    Livingston RB; Barlow WE; Kash JJ; Albain KS; Gralow JR; Lew DL; Flaherty LE; Royce ME; Hortobagyi GN
    Breast Cancer Res Treat; 2011 Nov; 130(1):123-31. PubMed ID: 21826527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial.
    Saip P; Eralp Y; Sen F; Karaca H; Ozkan M; Cetin B; Benekli M; Kucukoner M; Isikdogan A; Un O; Basaran G; Onur H
    Breast; 2013 Oct; 22(5):628-33. PubMed ID: 23954396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centers.
    Huober J; Baumann M; Rochlitz C; Aebi S; Güth U; von Moos R; Müller A; von Rohr L; Widmer I; Thürlimann B
    Oncology; 2011; 81(3-4):160-6. PubMed ID: 22041972
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer.
    Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Bachleitner-Hoffmann T; Locker GJ; Rudas M; Mader R; Zielinski CC; Steger GG
    Breast Cancer Res Treat; 2007 May; 102(3):375-81. PubMed ID: 17028979
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy.
    Fumoleau P; Cortés-Funes H; Taleb AB; Chan S; Campone M; Pouget JC; Tubiana-Hulin M; Slabber CF; Caroff-Paraïso I; Alberts AS; Ben Ayed F
    Am J Clin Oncol; 2009 Aug; 32(4):375-80. PubMed ID: 19487917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer.
    Ferretti G; Papaldo P; Fabi A; Carlini P; Felici A; Cognetti F
    Oncologist; 2006; 11(7):853-4. PubMed ID: 16880245
    [No Abstract]   [Full Text] [Related]  

  • 52. A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer.
    Chan A
    Ann Oncol; 2007 Jul; 18(7):1152-8. PubMed ID: 17264064
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer.
    Blasinska-Morawiec M; Tubiana-Mathieu N; Fougeray R; Pinel MC; Bougnoux P
    Breast; 2013 Feb; 22(1):58-63. PubMed ID: 23195794
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab.
    Stemmler HJ; Stieber P; Lässig D; Heinemann V
    Onkologie; 2005 Feb; 28(2):95-7. PubMed ID: 15692222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Efficacy and safety of trastuzumab plus different chemotherapy regimens in treatment of the patients with HER-2-positive advanced breast cancer].
    Guo J; Xu B; Ma F; Fan Y; Yuan P; Wang J; Cai R; Li Q; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):372-6. PubMed ID: 25030594
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy.
    Acevedo-Gadea C; Hatzis C; Chung G; Fishbach N; Lezon-Geyda K; Zelterman D; DiGiovanna MP; Harris L; Abu-Khalaf MM
    Breast Cancer Res Treat; 2015 Feb; 150(1):157-67. PubMed ID: 25687356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer.
    Iorfida M; Bagnardi V; Balduzzi A; Dellapasqua S; Cardillo A; Luini A; Intra M; Minchella I; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2010 Apr; 19(2):128-32. PubMed ID: 20117001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
    Burstein HJ; Lieberman G; Slamon DJ; Winer EP; Klein P
    Ann Oncol; 2005 Nov; 16(11):1772-7. PubMed ID: 16150805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab.
    Munzone E; Nolè F; Sanna G; Goldhirsch A
    Breast; 2005 Oct; 14(5):380-3. PubMed ID: 16216740
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.
    Papaldo P; Fabi A; Ferretti G; Mottolese M; Cianciulli AM; Di Cocco B; Pino MS; Carlini P; Di Cosimo S; Sacchi I; Sperduti I; Nardoni C; Cognetti F
    Ann Oncol; 2006 Apr; 17(4):630-6. PubMed ID: 16410363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.